Fitness Trends Brain Health Devices Market | Page 2

• Brain Health Devices Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Brain Health Devices Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Increasing number of regulatory approvals for brain health devices is expected to drive growth
of the global brain health devices market
Most of hospitals and healthcare organizations implementing insertion of brain implants in
patients who are at a risk of developing neurological disorders, in order to provide artificial
control on the brain functioning. Moreover, regulatory approvals for innovative and advanced
brain health devices is expected to propel the brain health devices market growth in the near
future. For instance, in April 2019, GE Healthcare received the U.S. Food and Drug
Administration (FDA) 510(k) clearance for its Deep Learning Image Reconstruction engine on the
new Revolution Apex computed tomography (CT) device. Deep Learning Image Reconstruction
(DLIR), a next-generation image reconstruction option, uses a dedicated deep neural network
(DNN) to generate TrueFidelity CT Images.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/market-insight/brain-health-devices-market-1095
Market Dynamics
Increasing focus on product development and introduction of devices for monitoring brain
function are expected to contribute to growth of the global brain health devices market. For
instance, in February 2019, Medtronic plc. launched its Deep Brain Stimulation (DBS) device
which is a surgically implanted medical device for patients with refractory epilepsy. The DBS
therapy delivers controlled electrical pulses to the anterior nucleus of the thalamus (ANT),
which is a part of a vascular network involved in seizures. The product was approved by the
U.S. FDA in May 2018.